Search
for
Sort by
Research
210-240 / 1000+ resultsresearch Effect of Cuscuta reflexa Extract in Mitigating Testosterone-Induced Benign Prostatic Hyperplasia in Rats: Targeting Inflammation and Oxidative Stress
Cuscuta reflexa extract may help treat benign prostatic hyperplasia by reducing inflammation and oxidative stress.
research Benign Prostatic Hyperplasia and Sexual Dysfunction: Review of the Impact of New Medical and Surgical Therapies on Sexual Health
New BPH treatments have low sexual dysfunction risk but may not improve urinary symptoms as much as traditional surgery.
research 5α-reductase type 3 expression in human benign and malignant tissues: A comparative analysis during prostate cancer progression
The role of 5α-reductase-3 in prostate cancer is unclear and needs more research.
research PD57-09 NATIONAL SURGICAL QUALITY IMPROVEMENT PROGRAM SURGICAL RISK CALCULATOR POORLY PREDICTS COMPLICATIONS IN PATIENTS UNDERGOING RADICAL CYSTECTOMY WITH URINARY DIVERSION: THE CASE FOR A PROCEDURE-SPECIFIC RISK CALCULATOR
Finasteride use is linked to a lower risk of bladder cancer, especially in Caucasians and Hispanics.
research Modulation der Hitzesensitivität im Prostatakarzinom in vitro: Der Einfluss der Androgenachse
Androgen-modulating drugs do not significantly change the heat sensitivity of prostate cancer cells.
research S90 Urethral PSA production after radical prostatectomy
After prostate removal surgery, higher initial prostate size was linked to higher urethral PSA levels and more severe male pattern baldness.
research Dihydrotestosterone and the Concept of 5α–Reductase Inhibition in Human Benign Prostatic Hyperplasia
Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.
research Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by treatment with finasteride or flutamide.
research Gleason grading controversies: what the chemoprevention trials have taught us
Finasteride reduces prostate cancer risk by 30% without affecting Gleason scores.
research Advances in structure-based drug design targeting membrane protein markers in prostate cancer
research Understanding the Epidemiology, Natural History, and Key Pathways Involved in Prostate Cancer
Prostate cancer was a major health issue in 2009, especially for Black men, and targeting the 5alpha-reductase enzyme could help in its prevention and treatment.
research The use of saw palmetto versus finasteride for the treatment of prostatitis/chronic pelvic pain syndrome
research Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
research Hormonal manipulation of benign prostatic hyperplasia
Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.
research Testosterone-stimulated weanlings as an alternative to castrated male rats in the Hershberger anti-androgen assay
Using testosterone-stimulated weanling rats can effectively replace castrated rats for anti-androgen testing, reducing animal stress.
research Effects of androgen deprivation on chronic bacterial prostatitis in a rat model
Finasteride and levofloxacin effectively reduce chronic bacterial prostatitis severity.
research Editorial Comment
Finasteride significantly reduces prostate cancer risk.
research 411 THE POTENTIAL OF CIRCULATING ENDOTHELIAL CELLS AS PROGNOSTIC BIOMARKERS IN PROSTATE CANCER
CEC levels may be a useful marker for predicting prostate cancer progression.
research 842Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS)
research MP09-16 5-ALPHA REDUCTASE INHIBITORS FOR MALE LOWER URINARY TRACT SYMPTOMS: A COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS
5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
research Control of testosterone 5alpha-reductase activity in the human hyperplastic prostate
Inhibiting testosterone 5alpha-reductase may help treat benign prostatic hyperplasia.
research Level-1 Data From the REDUCE Study and the PCPT Data
Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.
research Comparison of Intra-operative Blood Loss in Patients Undergoing Mono-Polar TURP with and without Pre-operative 2 Weeks Use of Finasteride
Taking Finasteride before surgery reduces blood loss and surgery time.
research Suprapubic Hair as a Supplementary Donor Source in Body Hair Follicular Unit Extraction: A Case Report
Suprapubic hair can be used as an extra donor source for hair transplants when scalp hair is limited.
research Additional Intraoperative Autologous-Derived Platelet-Rich Stroma to Transanal Flap Repair for the Treatment of Cryptoglandular Transsphincteric Fistulas in a Tertiary Referral Center: Long-Term Outcomes of a Prospective Pilot Study
Combining PRS with TAFR is promising for treating complex fistulas, with most patients achieving long-term healing.
research 5α-Reductase Inhibitors and Chemoprevention: The PCPT and Beyond
5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
research Prostatic irradiation-induced sexual dysfunction: A review and multidisciplinary guide to management in the radical radiotherapy era (Part III on Psychosexual Therapy and the Masculine Self-Esteem)
Prostate cancer patients need early psychological and sexual support during radiotherapy to improve their quality of life.
research Prospective investigation of risk factors for prostate cancer in the UK Biobank cohort study
Black ethnicity, prior PSA tests, enlarged prostate, and family history increase prostate cancer risk; Asian ethnicity, obesity, smoking, diabetes, and less sexual activity or no children decrease risk.
research Review: Adding α1-blockers to 5α-reductase inhibitors improves lower urinary tract symptoms in men
Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.